Skip to search formSkip to main contentSkip to account menu

lurtotecan liposome

Known as: liposomal lurtotecan, liposome, lurtotecan 
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
2005
2005
2074 Background: OSI-211 is a topoisomerase (topo) I inhibitor in liposomal formulation. In vivo efficacy of the liposomal… 
2005
2005
5017 Background: OSI-211 is a liposomal formulation of lurtotecan, a topoisomerase-I inhibitor. In a previous randomised dose… 
Highly Cited
2004
2004
2004
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… 
2001
2001
  • John P DesjardinsElizabeth A Abbott Frank C Richardson
  • Anti-Cancer Drugs
  • 2001
  • Corpus ID: 40347972
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan…